Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Novartis Ag ADR (NVS)

Novartis Ag ADR (NVS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 186,924,288
  • Shares Outstanding, K 2,236,739
  • Annual Sales, $ 49,898 M
  • Annual Income, $ 8,072 M
  • 60-Month Beta 0.54
  • Price/Sales 3.81
  • Price/Cash Flow 10.85
  • Price/Book 3.78
Trade NVS with:

Options Overview Details

View History
  • Implied Volatility 17.76%
  • Historical Volatility 12.86%
  • IV Percentile 47%
  • IV Rank 8.00%
  • IV High 66.00% on 12/16/20
  • IV Low 13.56% on 07/02/21
  • Put/Call Vol Ratio 0.33
  • Today's Volume 13,266
  • Volume Avg (30-Day) 4,611
  • Put/Call OI Ratio 0.24
  • Today's Open Interest 59,161
  • Open Int (30-Day) 43,536

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/21
See More
  • Average Estimate 1.64
  • Number of Estimates 2
  • High Estimate 1.68
  • Low Estimate 1.61
  • Prior Year 1.52
  • Growth Rate Est. (year over year) +7.89%

Price Performance

See More
Period Period Low Period High Performance
1-Month
81.97 +1.17%
on 09/20/21
93.65 -11.45%
on 08/31/21
-9.22 (-10.01%)
since 08/24/21
3-Month
81.97 +1.17%
on 09/20/21
95.17 -12.86%
on 08/17/21
-9.53 (-10.31%)
since 06/24/21
52-Week
77.04 +7.65%
on 10/30/20
98.52 -15.82%
on 01/25/21
-3.37 (-3.90%)
since 09/24/20

Most Recent Stories

More News
Pharma Stock Roundup: PFE Booster Jab Gets FDA Nod, JNJ's New Data on COVID-19 Shot

FDA grants EUA to Pfizer (PFE)/BioNTech's COVID-19 vaccine booster shots for limited use. J&J (JNJ) announces phase III data on booster dose of its single-shot vaccine.

AZN : 60.35 (+1.46%)
NVS : 82.93 (-0.77%)
JNJ : 164.36 (-0.30%)
PFE : 43.94 (-0.57%)
LLY : 231.68 (-0.22%)
ABBV : 107.07 (-0.27%)
BNTX : 333.48 (-5.53%)
Down More Than 8% in the Past Month, Should You Scoop Up Shares of Merck & Co?

Health care company Merck & Co’s (MRK) shares have declined more than 8% in price over the past month. However, the company made several advancements and reported impressive top-line growth across its...

MRK : 73.61 (+0.77%)
JNJ : 164.36 (-0.30%)
NVS : 82.93 (-0.77%)
ABT : 124.37 (-0.74%)
Incyte (INCY) Jakafi Wins FDA Approval for Chronic GVHD

Incyte's (INCY) going gets good with another FDA approval - Jakafi for the treatment of chronic GVHD. However, the stock witnesses a decline despite the recent approvals.

NVS : 82.93 (-0.77%)
BMY : 60.23 (-0.66%)
INCY : 69.00 (-1.12%)
MOR : 12.18 (-2.40%)
The Zacks Analyst Blog Highlights: Facebook, Walmart, Novartis, PayPal and Advanced Micro Devices

The Zacks Analyst Blog Highlights: Facebook, Walmart, Novartis, PayPal and Advanced Micro Devices

NVS : 82.93 (-0.77%)
AMD : 105.80 (-0.33%)
WMT : 143.17 (+0.28%)
FB : 352.96 (+2.02%)
PYPL : 278.11 (-0.35%)
Top Research Reports for Facebook, Walmart & Novartis

Today's Research Daily features new research reports on 16 major stocks, including Facebook, Inc. (FB), Walmart Inc. (WMT), and Novartis AG (NVS).

NVS : 82.93 (-0.77%)
AMD : 105.80 (-0.33%)
WMT : 143.17 (+0.28%)
AXP : 175.72 (+1.36%)
FB : 352.96 (+2.02%)
PYPL : 278.11 (-0.35%)
Global Immunotherapy Drugs Market Report Analysis, Share, Revenue, Growth Rate With Forecast Overview 2029

Research Nester published a report titled which delivers detailed overview of the global immunotherapy drugs market in terms of market segmentation by type, therapy area, and by region.

MRK : 73.61 (+0.77%)
GILD : 71.19 (-0.70%)
PFE : 43.94 (-0.57%)
AZN : 60.35 (+1.46%)
BMY : 60.23 (-0.66%)
GSK : 38.39 (-2.41%)
RHHBY : 46.0100 (-0.88%)
NVS : 82.93 (-0.77%)
BAYRY : 13.7100 (-0.22%)
Novartis presents new Kisqali® data showing longest median overall survival ever reported in HR+/HER2- advanced breast cancer

/PRNewswire/ -- Novartis today announced results of the final overall survival (OS) analysis of the Phase III MONALEESA-2 study, which evaluated Kisqali (ribociclib) in combination with letrozole compared...

NVS : 82.93 (-0.77%)
BeiGene (BGNE) Scores Third FDA Nod for Brukinsa in Lymphoma

The FDA grants accelerated nod to BeiGene's (BGNE) Brukinsa for treating adults with relapsed or refractory marginal zone lymphoma. This marks the third approval for the drug in the United States.

NVS : 82.93 (-0.77%)
BGNE : 379.52 (-1.53%)
CRVS : 6.80 (-3.27%)
SPRO : 18.73 (-4.00%)
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

NVS : 82.93 (-0.77%)
Ophthalmology Equipment Market Expected Growth and its Factors, CAGR, Industry Size, Business Prospects and Forecast 2029

Research Nester published a report titled ": Global Demand Analysis & Opportunity Outlook 2029" which delivers detailed overview of the global ophthalmology equipment market in terms of market segmentation...

NVS : 82.93 (-0.77%)
CZMWY : 223.6700 (-4.74%)
HOCPY : 168.3500 (-0.63%)
PFE : 43.94 (-0.57%)
ABBV : 107.07 (-0.27%)
SNPHY : 14.8500 (+0.13%)
TOPCF : 17.8700 (-1.08%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Average short term outlook on maintaining the current direction.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Business Summary

Novartis AG is committed to improving health and well-being through innovative products and services. The company aspires to capture and hold a leadership position in all of their businesses with a strong, sustainable performance based on continuous innovation. Their long-term success is founded on...

See More

Key Turning Points

3rd Resistance Point 84.20
2nd Resistance Point 83.94
1st Resistance Point 83.43
Last Price 82.93
1st Support Level 82.66
2nd Support Level 82.40
3rd Support Level 81.89

See More

52-Week High 98.52
Fibonacci 61.8% 90.31
Fibonacci 50% 87.78
Fibonacci 38.2% 85.25
Last Price 82.93
52-Week Low 77.04

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar